Artivion Inc
NYSE:AORT

Watchlist Manager
Artivion Inc Logo
Artivion Inc
NYSE:AORT
Watchlist
Price: 36.56 USD -5.77%
Market Cap: $1.8B

EV/EBITDA

39.5
Current
33%
More Expensive
vs 3-y average of 29.7

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
39.5
=
Enterprise Value
$2B
/
EBITDA
$49.2m

Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.

EV/EBITDA
39.5
=
Enterprise Value
$2B
/
EBITDA
$49.2m

Valuation Scenarios

Artivion Inc is trading above its 3-year average

If EV/EBITDA returns to its 3-Year Average (29.7), the stock would be worth $27.51 (25% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-67%
Maximum Upside
No Upside Scenarios
Average Downside
46%
Scenario EV/EBITDA Value Implied Price Upside/Downside
Current Multiple 39.5 $36.56
0%
3-Year Average 29.7 $27.51
-25%
5-Year Average 28.9 $26.73
-27%
Industry Average 12.9 $11.92
-67%
Country Average 14.4 $13.28
-64%

Forward EV/EBITDA
Today’s price vs future ebitda

Today's Enterprise Value EBITDA Forward EV/EBITDA
$2B
/
Jan 2026
$49.2m
=
39.5
Current
$2B
/
Dec 2026
$106.5m
=
18.7
Forward
$2B
/
Dec 2027
$127.7m
=
15.6
Forward
$2B
/
Dec 2028
$152.2m
=
13.1
Forward

Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.

Peer Comparison

All Multiples
EV/EBITDA
P/E
All Countries
Close
Market Cap EV/EBITDA P/E
US
Artivion Inc
NYSE:AORT
1.7B USD 39.5 179.3
US
Abbott Laboratories
NYSE:ABT
161B USD 13.9 25.4
US
Intuitive Surgical Inc
NASDAQ:ISRG
160.3B USD 45.6 60.1
US
Stryker Corp
NYSE:SYK
125.2B USD 19.8 38.8
IE
Medtronic PLC
NYSE:MDT
105.2B USD 12.8 23.1
US
Boston Scientific Corp
NYSE:BSX
88.3B USD 19.5 32.9
DE
Siemens Healthineers AG
XETRA:SHL
41.6B EUR 11.1 19.7
US
Edwards Lifesciences Corp
NYSE:EW
46.3B USD 24 44
US
IDEXX Laboratories Inc
NASDAQ:IDXX
45.4B USD 30.7 43.4
US
Becton Dickinson and Co
NYSE:BDX
44.6B USD 10 25.1
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
32.9B USD 11.2 15.6

Market Distribution

Higher than 84% of companies in the United States of America
Percentile
84rd
Based on 9 875 companies
84rd percentile
39.5
Low
0 — 10
Typical Range
10 — 21.5
High
21.5 —
Distribution Statistics
the United States of America
Min 0
30th Percentile 10
Median 14.4
70th Percentile 21.5
Max 1 767 274.1

Artivion Inc
Glance View

Market Cap
1.8B USD
Industry
Health Care

In the heart of the biomedical landscape, Artivion Inc. emerges as a company fervently dedicated to extending and saving lives through advanced medical technologies. It is a principal innovator and supplier in cardiac and vascular surgery, carving its niche by providing unique products that serve critical therapeutic needs. Initially branded as CryoLife, the company redefined its mission and vision under the Artivion name post a strategic transformation, focusing on strategically enhancing its product portfolio. It crafts precision-engineered prosthetic heart valves, notably the On-X mechanical valve, which is renowned for its exceptional long-term durability and performance in reducing the need for anticoagulation therapy. Through its relentless innovation, Artivion ensures that its offerings are not only of high quality but also cost-effective, thereby widening the accessibility to life-saving technologies. This commitment to quality is underscored by their rigorous research and development efforts and regulatory compliance, ensuring every product meets global medical standards. Artivion's revenue engine is driven largely by its cardiovascular implantables and bioprosthetics used in vascular surgery, alongside tissue processing services that provide mitral, aortic, and pulmonary cardiac valves. By coupling advanced materials and sophisticated design, the organization enhances its presence in the global cardiovascular industry—serving hospitals, physicians, and patients alike. Its products are distributed through a combination of direct sales and distributor partnerships, broadening its geographical market presence from the United States to Europe, Asia, and beyond. Artivion stands not only as a supplier but as a strategic partner to clinicians, extending support and education to ensure optimal patient outcomes. Its strategic prowess in the competitive med-tech arena is an intricate mosaic of innovation, operational excellence, and a keen awareness of the pressing health challenges that afflict the global population. Through these concerted efforts, Artivion not only sustains its growth and shareholder value but continues its mission to improve life expectancy and quality around the world.

AORT Intrinsic Value
23.44 USD
Overvaluation 36%
Intrinsic Value
Price $36.56
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett